Ozone Depletion Potential
 |
|
 |
Ozone Depleting Substances (ODSs)/Ozone Depletion Potential
(ODP)
Ozone depleting substances (ODSs), as defined by the Montreal
Protocol and its Amendments, have been measured from their sources
in manufacturing operations and research & development facilities.
Ozone depleting substances are released to the atmosphere from production
operations (primarily production of metered dose inhalers), ancillary
cooling systems and fire suppressant systems at GSK facilities.
We report ozone depletion potential in CFC-11 equivalents as defined
by the United Nations Environment Programme (UNEP) Ozone Secretariat
(www.ghgprotocol.org
and www.ipcc.ch).
In addition to the ozone depletion potential
from production and ancillary releases, the ozone depletion potential
from propellant released when patients used our products in 2003
was 782 thousand kilograms. This is a significant decrease from
1.5 million kilograms in 2002 and 1.9 million kilograms in 2001
also due to the change to CFC free and dry powder inhalers.
In 2001, we set two targets related to ozone depleting substances
to be achieved by the end of 2005; 50% reduction in CFC-11 equivalent
emissions related to production processes and elimination (100%
reduction) of CFC emissions related to refrigeration and other ancillary
processes.
Ozone
Depletion Potential from Ancillary Use |
 |
|
For 2002, the ODP from ancillary releases was 7.4 thousand
kilograms representing a 15.6% increase in CFC-11 equivalent
releases from 2001. For 2003, the figure is 2.3 thousand
kilograms, a reduction of 69% from 2002 and 64% from
the 2001 baseline. In 2002, a one-time facility maintenance
activity occurred at one of our major manufacturing
sites. This facility alone accounted for nearly 30%
of the GSK total for ancillary ODP release in 2002.
Facility maintenance activities will continue to occur
in the future but GSK endeavours to keep a priority
on this issue toward meeting the 2005 target to eliminate
ancillary releases of CFCs.
|
In 2001, GSK released 892.7 kilograms of CFC-11 and CFC-12 combined, related to ancillary use and in 2003 this was reduced to 347.2 kilograms of CFC-11 and CFC-12 combined. In addition to CFC-11 and CFC-12 the following amounts of ozone depleting substances (substances having an ODP factor greater than zero) were released:
| Ozone depleting substances
released from ancillary activities * |
| HCFC
22 (R22) |
17,379 |
| HFC 123 (R123) |
341 |
| R408a |
2,169 |
| R403a |
100 |
| R502 |
247 |
| Halon 1211 |
90 |
| Others |
96 |
| *Substances
(in kilograms) with ozone depletion potentials
ranging from 0.02 to 3.0. |
|
In 2001 we set a target to eliminate CFC emissions related to ancilliary uses by the end of 2005 and we are making progress toward achievement of that target.
|
|
|
History of data changes
For refrigeration and other ancillary releases
of halocarbons we reported 7.8 thousand kilograms of ozone depletion
potential (CFC-11 equivalents) in 2001. During the reporting process
in both 2002 and 2003, sites took the opportunity to review their
releases for 2001 and some sites made revisions. In addition, we
corrected some of the factors that were used to calculate the ODP
values, applied them more consistently for all years and applied
more specific factors to individual ozone depleting substances
rather than general factors to groups of substances and reclassified
some production ozone depleting substances to ancillary use. Because
of these corrections the 2001 baseline was revised to 5 thousand
kilograms in the 2002 report and to 6.4 thousand kilograms this
year.
Ozone
Depletion Potential from Ancillary Use by Business
|
 |
Ozone
Depletion Potential from Production Use |
 |
|
Production process-related CFC-11 equivalent
emissions have decreased from 120 thousand kilograms
in 2002 to 68 thousand kilograms representing a 43%
reduction. The decrease since 2001 baseline year is
62%. In 2001, GSK released 178,452 kilograms of CFC-11
and CFC-12 as part of production activities and reduced
this to 67,380 kilograms of CFC-11 and CFC-12 in 2003.
This decrease is primarily due to changes at our main
inhaler manufacturing facilities from production of
CFC inhalers to CFC free and dry powder inhalers. In
addition to CFC-11 and CFC-12 the following amounts
of ozone depleting substances (substances having an
ODP factor greater than zero) were released from production-related
activities:
|
| Ozone depleting substances released
from production activities* |
| Methyl bromide |
670 |
| 1,1,1 Trichloroethane |
504 |
| Others |
430 |
| * Substances
(in kilograms) with ozone depletion potentials
ranging from 0.1 to 0.6. |
|
|
In 2001 we set a target to reduce ozone depletion potential from production activities by 50% on a per unit sales basis by the end of 2005 and we have exceeded that target in 2003.
|
|
|
Ozone
Depletion Potential from Production Use by Business |
 |
|
